MLAB 📈 Mesa Laboratories - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US59064R1095
MLAB: Life Sciences Tools, Quality Control Products, Laboratory Services
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado. Web URL: https://www.mesalabs.com
Additional Sources for MLAB Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
MLAB Stock Overview
Market Cap in USD | 636m |
Sector | Technology |
Industry | Scientific & Technical Instruments |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception | 1995-01-25 |
MLAB Stock Ratings
Growth 5y | -47.7% |
Fundamental | -14.3% |
Dividend | 34.5% |
Rel. Strength Industry | 482 |
Analysts | 3.5/5 |
Fair Price Momentum | 117.68 USD |
Fair Price DCF | 170.43 USD |
MLAB Dividends
Dividend Yield 12m | 0.48% |
Yield on Cost 5y | 0.26% |
Annual Growth 5y | 0.00% |
Payout Consistency | 96.2% |
MLAB Growth Ratios
Growth Correlation 3m | -15.9% |
Growth Correlation 12m | 66.6% |
Growth Correlation 5y | -79.8% |
CAGR 5y | -11.60% |
CAGR/Mean DD 5y | -0.33 |
Sharpe Ratio 12m | 0.62 |
Alpha | 5.39 |
Beta | 0.77 |
Volatility | 54.89% |
Current Volume | 141.8k |
Average Volume 20d | 44.5k |
What is the price of MLAB stocks?
As of December 21, 2024, the stock is trading at USD 132.08 with a total of 141,805 shares traded.
Over the past week, the price has changed by +3.54%, over one month by +34.15%, over three months by +2.87% and over the past year by +29.95%.
As of December 21, 2024, the stock is trading at USD 132.08 with a total of 141,805 shares traded.
Over the past week, the price has changed by +3.54%, over one month by +34.15%, over three months by +2.87% and over the past year by +29.95%.
Is Mesa Laboratories a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Mesa Laboratories is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -14.29 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MLAB as of December 2024 is 117.68. This means that MLAB is currently overvalued and has a potential downside of -10.9%.
Neither. Based on ValueRay Fundamental Analyses, Mesa Laboratories is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -14.29 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MLAB as of December 2024 is 117.68. This means that MLAB is currently overvalued and has a potential downside of -10.9%.
Is MLAB a buy, sell or hold?
Mesa Laboratories has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold MLAB.
Mesa Laboratories has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold MLAB.
- Strong Buy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 1
What are the forecast for MLAB stock price target?
According to ValueRays Forecast Model, MLAB Mesa Laboratories will be worth about 128.2 in December 2025. The stock is currently trading at 132.08. This means that the stock has a potential downside of -2.92%.
According to ValueRays Forecast Model, MLAB Mesa Laboratories will be worth about 128.2 in December 2025. The stock is currently trading at 132.08. This means that the stock has a potential downside of -2.92%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 133.3 | 0.9% |
Analysts Target Price | 139 | 5.2% |
ValueRay Target Price | 128.2 | -2.9% |